Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Clinical evidence

Voyage

78 evidence topics · 17 sources

Objective
Location and study date
Registered study dates
FieldQuoted record
Study start (actual)“2024-12-11”
Primary completion (actual)“2026-07-15”
Study completion (estimated)“2027-04”
Recruitment status“Active, not recruiting”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using hamilton anxiety rating scale total score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Analyzed: all randomized participants in the intention-to-treat population
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics and baseline characteristics: ITT population
CharacteristicDT120 ODT (n = 107)Placebo ODT (n = 107)Overall (N = 214)
Age, mean (range), years“42 (21–72)”“43 (20–67)”“42 (20–72)”
Female, n (%)“63 (59)”“74 (69)”“137 (64)”
Male, n (%)“44 (41)”“33 (31)”“77 (36)”
White, n (%)“78 (73)”“77 (72)”“155 (72)”
Black or African American, n (%)“9 (8)”“19 (18)”“28 (13)”
Asian, n (%)“8 (7)”“9 (8)”“17 (8)”
Baseline HAM-A score, mean (SD)“28.4 (5.9)”“27.4 (5.5)”“27.9 (5.7)”
Moderate GAD (HAM-A <24), n (%)“26 (24)”“28 (26)”“54 (25)”
Severe GAD (HAM-A ≥24), n (%)“81 (76)”“79 (74)”“160 (75)”
Baseline CGI-S score, mean (SD)“4.6 (0.6)”“4.6 (0.6)”“4.6 (0.6)”
Past use of any psychedelic, n (%)“18 (17)”“27 (25)”“45 (21)”
Past LSD use, n (%)“10 (9)”“9 (8)”“19 (9)”
No past GAD medications, n (%)“35 (33)”“36 (34)”“71 (33)”
One past GAD medication, n (%)“31 (29)”“34 (32)”“65 (30)”
Two or more past GAD medications, n (%)“41 (38)”“37 (35)”“78 (36)”
Comorbid MDD, n (%)“43 (40)”“37 (35)”“80 (37)”
Years since GAD diagnosis, mean (SD)“11.1 (10.1)”“12.9 (11.6)”“12.0 (10.9)”
Years since onset of GAD symptoms, mean (SD)“21.9 (13.7)”“25.7 (14.4)”“23.8 (14.1)”
Baseline MADRS score
CharacteristicDT120 ODT (n=107)Placebo ODT (n=107)Overall (n=214)
MADRS score, mean (SD)“13.6 (4.6)”“13.5 (4.4)”“13.5 (4.5)”
Characteristics at Part B entry: interim analysis
CharacteristicDT120 ODT in Part A (n=62)Placebo ODT in Part A (n=75)Total (n=137)
Mean age (years)“40.9”“43.6”“42.3”
Sex, female (%)“52%”“68%”“61%”
Race (% white)“76%”“76%”“76%”
HAM-A score at Part B entry“16.8”“21.2”“n/a”
CGI-S score at Part B entry“3.6”“4.2”“n/a”
Efficacy results
Primary and key secondary endpoints: Part A
EndpointDT120 ODT 100 µgPlacebo ODTPlacebo-adjusted difference
HAM-A: LS mean change at Week 12 (primary)“-11.6”“-6.2”“-5.4 (p<.0001)”
CGI-S: LS mean change at Week 12 (key secondary)“-1.0”“-0.4”“-0.6 (p<.0001)”
HAM-A: LS mean change at Week 1 (key secondary)“-11.9”“-4.2”“-7.7 (p<.0001)”
CGI-S: LS mean change at Day 2 (key secondary)“-1.0”“-0.2”“-0.8 (p<.0001)”
Response, remission, and mild or better at Week 12
EndpointDT120 ODT 100 µgPlacebo ODTPlacebo-adjusted difference
HAM-A response rate (≥50%) at Week 12“43%”“16%”“27% (p<0.0001)”
HAM-A remission rate (≤7) at Week 12“14%”“4%”“10% (p=0.0222)”
HAM-A mild or better (<16) at Week 12“51%”“23%”“28% (p<0.0001)”
Subgroup analyses: placebo-adjusted change in HAM-A at Week 12
SubgroupPlacebo-adjusted change in LS mean (SE)
All participants“−5.4 (1.0)”
Time since GAD symptoms began <22 years (n = 107)“−5.9 (1.4)”
Time since GAD symptoms began ≥22 years (n = 107)“−4.7 (1.5)”
Previous GAD medications <2 (n = 136)“−4.2 (1.2)”
Previous GAD medications ≥2 (n = 78)“−5.6 (1.7)”
Male (n = 77)“−7.1 (1.7)”
Female (n = 137)“−5.5 (1.2)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events of special interest: topline presentation value
Adverse eventDT120 ODT (n=107)Placebo ODT (n=107)
Any Adverse Event of Special Interest (AESI)“100 (94%)”“30 (28%)”
TEAEs with incidence of 10% or more, on the dosing day and after it
TEAEDosing day: DT120 ODT (n=107)Dosing day: placebo ODT (n=107)After dosing day: DT120 ODT (n=107)After dosing day: placebo ODT (n=107)
Illusion“80 (75%)”“11 (10%)”“2 (2%)”“0”
Nausea“41 (38%)”“9 (8%)”“3 (3%)”“3 (3%)”
Euphoric mood“28 (26%)”“4 (4%)”“0”“0”
Headache“26 (24%)”“7 (7%)”“12 (11%)”“7 (7%)”
Feeling abnormal“21 (20%)”“3 (3%)”“0”“0”
Disorientation“19 (18%)”“2 (2%)”“1 (1%)”“0”
Dizziness“14 (13%)”“5 (5%)”“1 (1%)”“1 (1%)”
Crying“13 (12%)”“4 (4%)”“0”“0”
Thinking abnormal“12 (11%)”“1 (1%)”“0”“0”
Paraesthesia“12 (11%)”“4 (4%)”“0”“0”
Feeling of body temperature change“12 (11%)”“1 (1%)”“0”“0”
Anxiety“11 (10%)”“2 (2%)”“3 (3%)”“0”
Feeling of relaxation“8 (8%)”“12 (11%)”“1 (1%)”“0”
Hallucination, visual“9 (8%)”“2 (2%)”“1 (1%)”“0”
Insomnia“7 (7%)”“0”“1 (1%)”“6 (6%)”
Emotional disorder“6 (6%)”“1 (1%)”“1 (1%)”“0”
Study limitations
Summary
  • Publication status: results come from company topline announcements, presentations, and filings and from a report of the Voyage topline results; one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results.
  • Functional unblinding: Voyage used a two-arm design of DT120 100 µg versus placebo without the 50 µg low-dose comparator used in Panorama. Study drug-related TEAEs occurred in 95% of participants receiving DT120 and 48% receiving placebo, and illusion occurred on the dosing day in 75% and 10%. Baseline expectancy and perceived treatment were recorded; the cited disclosures report no results of these assessments. Central HAM-A raters were blinded to treatment assignment and visit number. Past psychedelic use was reported by 21% of participants.
  • Duration and dosing: the controlled comparison covers 12 weeks after a single dose. Part B is open label, and its results come from an interim analysis as of July 15, 2026, with 37 participants who received DT120 in Part A contributing HAM-A data at Week 28.
  • Comparator: placebo was the only comparator; no active GAD treatment was included. The placebo group improved by 6.2 points on HAM-A at Week 12.
  • Generalizability: participants were 18 to 74 years of age at approximately 35 sites in the United States, and people taking medications with anxiolytic or antidepressant effects that could not be discontinued, people with a personal or first-degree family history of psychotic or bipolar disorder, people with current alcohol or substance use disorder, and people in systematic psychotherapy within 4 weeks before screening were excluded.
  • Outcomes not reported in the cited disclosures: registered patient-reported, functioning, quality of life (PGI-S, WPAI-SHP, EQ-5D-5L), and sexual functioning (CSFQ-14) endpoints. The sponsor stated that Part B safety data are expected to be shared in a future presentation.
  • Discrepancies between sources: the share of participants clearing the end-of-session checklist by hour 8 is 92% in the topline announcement and 90% in the poster, and adverse events of special interest with DT120 are 100 (94%) in the topline presentation and 100 (93) in the poster.